Clinical trials have demonstrated that SGLT2 inhibitors lead not only to weight loss but also to a reduction in blood pressure, making them a valuable option for patients with type 2 diabetes who are also overweight or hypertensive [52]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.